-
UPDATE: BMO Capital Upgrades Applied Genetic Technologies Corp. (AGTC) to Outperform
-
AGTC to Present at BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference on June 25, 2019
-
BMO Capital Downgrades Applied Genetic Technologies Corp. (AGTC) to Market Perform
-
Applied Genetic Technologies Corp. (AGTC) PT Raised to $13 at BMO Capital After Adding XLRP to Valuatoin
-
AGTC to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14, 2017
-
AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2017
-
UPDATE: Applied Genetic Technologies Corp. (AGTC) PT Lowered to $7 at BMO Capital; Lower Probability of XLRS Success
-
Applied Genetic Technologies Corp. (AGTC) PT Lowered to $14 at BMO Capital
-
BMO Capital Remains Bullish on Applied Genetic Technologies (AGTC) Following Investor Meetings
-
AGTC to Present at Upcoming Conferences
-
BMO Capital Cuts Price Target on Applied Genetic Technologies (AGTC) to $20
-
BMO Capital Starts Applied Genetic Technologies Corp. (AGTC) at Outperform
-
Applied Genetic Technologies (AGTC) PT Lifted to $42 at BMO Capital on 'Transformational' Deal with Biogen (BIIB)
-
AGTC Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Applied Genetic Technologies (AGTC) Prices 2M Common Offering at $15/Share
-
AGTC Announces Pricing of Public Offering
-
Notable Analyst Rating Changes 04/21: (MS) (AWI) (HNI) Upgraded; (WLT) (MGI) (YUM) Downgraded
-
UPDATE: BMO Capital Starts Applied Genetic Technologies Corp. (AGTC) at Outperform
-
AGTC Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Applied Genetic Technologies (AGTC) IPO Opens Higher
-
Applied Genetic Technologies (AGTC) IPO Prices at $12, Below Range
-
AGTC Announces Pricing of Initial Public Offering
-
Applied Genetic Technologies (AGTC) Files $70M IPO

